Developer docs
API playgroundTry for free, no card

Search company profiles

UPMC Enterprises

Full company profile

uuid0005g1g

Namestring
UPMC Enterprises
Legal namestring
UPMC Enterprises
Company typeenum
Private
Founded yearint
2015
Descriptiontext

UPMC Enterprises is the innovation, commercialization, and venture capital arm of UPMC, a $28 billion private healthcare provider and insurer headquartered in Pittsburgh. The firm operates two strategic focus areas — Translational Sciences (diagnostics and therapeutics) and Digital Solutions (digital health technologies) — and invests across stages from seed to growth through an evergreen capital model backed by the parent system. It serves healthcare startups needing capital, clinical validation pathways, and distribution access; pharmaceutical and biotech sponsors running industry-sponsored trials; and AI developers seeking high-quality real-world clinical data.

The firm's core technology asset is Ahavi™, a real-world data platform providing secure access to de-identified clinical records from 5 million patients across 24 UPMC hospitals, including 156 million structured patient encounters and over 154 million ambulatory documents with structured-to-unstructured linkage rates of 80–99%. Datasets are normalized and delivered within 2–4 weeks. Supporting initiatives include the Center for Connected Medicine (a thought-leadership and events platform), the Pittsburgh Health Data Alliance with Carnegie Mellon and University of Pittsburgh, and the OnCore-based Sponsored Clinical Trials and Partnerships program activating 200–250 industry-sponsored trials annually across 25+ departments.

UPMC Enterprises generates revenue through venture capital returns on a portfolio spanning BrainCheck, Carta Healthcare, RAAPID, Penguin AI, Koda Health, Precede Biosciences, and Interra Health (formed from the DoseSpot–Arrive Health merger). Clinical trial services for pharmaceutical sponsors provide a second revenue stream, and Ahavi represents an emerging external commercialization surface. Investment and trial economics are not publicly disclosed.

Short descriptiontext

UPMC Enterprises is the venture and innovation arm of UPMC, investing across stages in healthcare AI, digital health, and therapeutics while commercializing the Ahavi real-world clinical data platform and running 200–250 industry-sponsored clinical trials annually.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersPittsburgh, United States
HQ citystring
Pittsburgh
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
healthcare venture capital, real-world data platform, clinical trial services, digital health investments, translational sciences
Industry2 codes
PRIMARYFSANAHAF
Corporate Strategic Partnership & Ecosystem Investment Arms
SECONDARYFSANAHAL
Corporate Deep Tech / R&D Commercialization CVC
NAICS code1 code
  • Management of Companies and Enterprises55111
SIC code1 code
  • Security Brokers, Dealers & Flotation Companies6211
Product category
Healthcare Venture Capital and Innovation Services
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Venture Capital Returns
TypeLicensing Royalties
Description

UPMC Enterprises generates returns through equity investments in healthcare innovation companies. As an evergreen investment platform, they deploy capital across therapeutics, digital health, and translational sciences, seeking to build and scale high-impact healthcare companies.

enterprises.upmc.com:443
2Clinical Trials Services
TypeProfessional Services
Description

UPMC activates approximately 200-250 industry-initiated sponsored trials annually, supporting complex multi-site research across more than 25 departments and UPMC Hillman Cancer Center.

enterprises.upmc.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
1Ahavi
Description

Real-world health care data platform providing secure access to de-identified clinical data from UPMC's patient population to accelerate discoveries and improve patient care.

enterprises.upmc.com
+2 more records
Core offering1 text field

UPMC Enterprises operates as the innovation, commercialization, and venture capital arm of UPMC, investing in early- to growth-stage healthcare companies across Therapeutics, Digital Health, and Translational Sciences. It also operates the Ahavi real-world healthcare data platform, which provides secure access to de-identified clinical data from UPMC's patient population, and manages the UPMC Sponsored Clinical Trials and Partnerships program for industry sponsors.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Ahavi delivers normalized and de-identified datasets within 2-4 weeks, significantly faster than traditional methods
+2 more records
Product overview1 text field

UPMC Enterprises operates as the innovation, commercialization, and venture capital arm of UPMC ($28 billion health system) with two strategic focus areas: Translational Sciences (diagnostics and therapeutics) and Digital Solutions. The core technology offering includes Ahavi™, a real-world data platform that provides secure access to de-identified clinical data from over 5 million patients across 24 hospitals, enabling AI model validation, clinical trial design, and healthcare R&D. Supporting initiatives include the Center for Connected Medicine (CCM) for industry collaboration and events, MyUPMC patient app, and the Pittsburgh Health Data Alliance research partnership. The investment portfolio spans digital health, biotech, and life sciences companies including BrainCheck (cognitive assessment), Carta Healthcare (clinical data abstraction), RAAPID (risk adjustment AI), and Penguin Ai (administrative automation).

Product and service3 records
1Ahavi Real-World Data Platform
CategoryHealthcare Data Platform
Description

Real-world healthcare data platform providing secure access to de-identified clinical data from UPMC's patient population (5M+ patients across 24 hospitals), enabling AI model validation, clinical trial design, and research acceleration by integrating structured and unstructured data from EHRs, radiology, and pathology reports.

2UPMC Sponsored Clinical Trials and Partnerships
CategoryClinical Trial Services
Description

Centralized clinical trial management program providing industry sponsors streamlined access to UPMC's clinical research infrastructure, featuring OnCore CTMS and Ahavi real-world data integration. Activates approximately 200-250 industry-sponsored trials annually across more than 25 departments.

3Healthcare Investment Portfolio
CategoryVenture Capital Investment
Description

Evergreen investment platform deploying capital from early- to growth-stage in healthcare innovation companies, providing portfolio companies with capital, connections, and resources including access to UPMC's clinical infrastructure for validation and pilots.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-12
Description

UPMC Enterprises entered a strategic partnership with Penguin AI to advance healthcare-specific AI models using UPMC's Ahavi secure data platform. Through the collaboration, Penguin AI leverages Ahavi to develop healthcare AI systems including Patient 360 and Enhanced Prior Authorization, designed to improve clinical decision-making and reduce administrative burdens.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

UPMC Enterprises participated as judges in the Forge to Field AI Pitch Competition hosted by Carnegie Mellon University's Swartz Center for Entrepreneurship and AI Strike Team, distributing over $1.75 million in potential investments during NFL Draft Week.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Nokia supports the Center for Connected Medicine at UPMC, collaborating with UPMC Enterprises to bring together leaders and innovators striving to advance healthcare through programming that informs, connects, and inspires.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

UPMC Enterprises and KLAS Research collaborate on healthcare research including reports on precision medicine, clinical trials, AI in healthcare, and ambulatory care strategies at health systems.

5Realyze Intelligence (Acquired by Carta Healthcare)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Carta Healthcare acquired Realyze Intelligence from UPMC Enterprises in November 2024 to expand into clinical trials. This built on prior collaboration in clinical data management.

memorialcareinnovationfund.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

The venture arm of OSF HealthCare, a large integrated Catholic health system. Direct peer because it invests in digital health and care delivery startups using OSF's clinical network, very similar in structure and scale to UPMC Enterprises.

TypeDirect peer
Description

The corporate venture arm of UnitedHealth Group's Optum, investing across healthcare AI, digital health, and care delivery. Direct peer because it operates the same model: a CVC funded by a major integrated payer-provider, leveraging clinical and data assets to back healthcare innovation companies.

TypeDirect peer
Description

The technology transfer and venture arm of Mayo Clinic. Direct peer because it commercializes clinical innovations and invests in healthcare startups using Mayo's clinical research infrastructure—essentially the same role UPMC Enterprises plays within UPMC.

TypeBroad incumbent
Description

A major independent venture firm with dedicated bio/health funds. Comparable in that it invests across the same healthcare AI and biotech categories that UPMC Enterprises targets, but at much greater scale and from a pure-financial-return perspective.

TypeBroad incumbent
Description

A leading independent VC with a dedicated health system transformation practice partnering with major US health systems. Adjacent to UPMC Enterprises because it competes for healthcare AI and digital health deals, though it operates without corporate-parent backing.

TypeDirect peer
Description

The strategic venture arm of Kaiser Permanente, one of the largest integrated US health systems. Direct peer because it invests across healthcare technology and services using Kaiser's clinical infrastructure and patient population, mirroring UPMC Enterprises' model.

TypeDirect peer
Description

The commercialization and venture arm of Cleveland Clinic. Direct peer because it spins out and invests in healthcare companies leveraging Cleveland Clinic's clinical expertise and IP, paralleling UPMC Enterprises' Translational Sciences function.

TypeDirect peer
Description

The innovation and venture arm of Memorial Hermann Health System. Comparable to UPMC Enterprises as a regional health system-backed CVC deploying capital and clinical infrastructure into digital health and care delivery startups.

9Geisinger Ventures
TypeDirect peer
Description

The investment and commercialization arm of Geisinger Health. Comparable to UPMC Enterprises as a Pennsylvania-based integrated health system CVC focused on healthcare technology innovation and translational research.

TypeBroad incumbent
Description

Major independent venture firm with a substantial healthcare practice. Comparable to UPMC Enterprises in that it actively invests across healthcare AI, biotech, and digital health—but operates as an independent VC rather than a corporate subsidiary.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability9 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles20 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment55 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

UPMC Enterprises

Healthcare Venture Capital and Innovation Servicesenterprises.upmc.com

UPMC Enterprises is the venture and innovation arm of UPMC, investing across stages in healthcare AI, digital health, and therapeutics while commercializing the Ahavi real-world clinical data platform and running 200–250 industry-sponsored clinical trials annually.

What UPMC Enterprises does

UPMC Enterprises is the innovation, commercialization, and venture capital arm of UPMC, a $28 billion private healthcare provider and insurer headquartered in Pittsburgh. The firm operates two strategic focus areas — Translational Sciences (diagnostics and therapeutics) and Digital Solutions (digital health technologies) — and invests across stages from seed to growth through an evergreen capital model backed by the parent system. It serves healthcare startups needing capital, clinical validation pathways, and distribution access; pharmaceutical and biotech sponsors running industry-sponsored trials; and AI developers seeking high-quality real-world clinical data.

The firm's core technology asset is Ahavi™, a real-world data platform providing secure access to de-identified clinical records from 5 million patients across 24 UPMC hospitals, including 156 million structured patient encounters and over 154 million ambulatory documents with structured-to-unstructured linkage rates of 80–99%. Datasets are normalized and delivered within 2–4 weeks. Supporting initiatives include the Center for Connected Medicine (a thought-leadership and events platform), the Pittsburgh Health Data Alliance with Carnegie Mellon and University of Pittsburgh, and the OnCore-based Sponsored Clinical Trials and Partnerships program activating 200–250 industry-sponsored trials annually across 25+ departments.

UPMC Enterprises generates revenue through venture capital returns on a portfolio spanning BrainCheck, Carta Healthcare, RAAPID, Penguin AI, Koda Health, Precede Biosciences, and Interra Health (formed from the DoseSpot–Arrive Health merger). Clinical trial services for pharmaceutical sponsors provide a second revenue stream, and Ahavi represents an emerging external commercialization surface. Investment and trial economics are not publicly disclosed.

UPMC Enterprises firmographics

Firmographics
Name
UPMC Enterprises
Legal name
UPMC Enterprises
Website
https://enterprises.upmc.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
101–250 employees
Short description
UPMC Enterprises is the venture and innovation arm of UPMC, investing across stages in healthcare AI, digital health, and therapeutics while commercializing the Ahavi real-world clinical data platform and running 200–250 industry-sponsored clinical trials annually.
Ownership category
akta.pro rank

UPMC Enterprises industry classification

Industry
Product category
Healthcare Venture Capital and Innovation Services
NAICS
Management of Companies and Enterprises (55111)
SIC
Security Brokers, Dealers & Flotation Companies (6211)
akta.pro industry
PRIMARYFSANAHAF
Corporate Strategic Partnership & Ecosystem Investment Arms
SECONDARYFSANAHAL
Corporate Deep Tech / R&D Commercialization CVC

Keywords

  • Healthcare venture capital
  • Real-world data platform
  • Clinical trial services
  • Digital health investments
  • Translational sciences

Where UPMC Enterprises is headquartered

Location

Headquarters

HQ city
Pittsburgh
HQ country
United States
HQ region
North America

Offices2 records

Markets served

UPMC Enterprises business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

  1. Venture Capital Returns: UPMC Enterprises generates returns through equity investments in healthcare innovation companies. As an evergreen investment platform, they deploy capital across therapeutics, digital health, and translational sciences, seeking to build and scale high-impact healthcare companies.
  2. Clinical Trials Services: UPMC activates approximately 200-250 industry-initiated sponsored trials annually, supporting complex multi-site research across more than 25 departments and UPMC Hillman Cancer Center.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

UPMC Enterprises product offering

Product offering

Core offering

UPMC Enterprises operates as the innovation, commercialization, and venture capital arm of UPMC, investing in early- to growth-stage healthcare companies across Therapeutics, Digital Health, and Translational Sciences. It also operates the Ahavi real-world healthcare data platform, which provides secure access to de-identified clinical data from UPMC's patient population, and manages the UPMC Sponsored Clinical Trials and Partnerships program for industry sponsors.

Product overview

UPMC Enterprises operates as the innovation, commercialization, and venture capital arm of UPMC ($28 billion health system) with two strategic focus areas: Translational Sciences (diagnostics and therapeutics) and Digital Solutions. The core technology offering includes Ahavi™, a real-world data platform that provides secure access to de-identified clinical data from over 5 million patients across 24 hospitals, enabling AI model validation, clinical trial design, and healthcare R&D. Supporting initiatives include the Center for Connected Medicine (CCM) for industry collaboration and events, MyUPMC patient app, and the Pittsburgh Health Data Alliance research partnership. The investment portfolio spans digital health, biotech, and life sciences companies including BrainCheck (cognitive assessment), Carta Healthcare (clinical data abstraction), RAAPID (risk adjustment AI), and Penguin Ai (administrative automation).

Differentiator

Problem solved

Functional benefit

Brands

  • Ahavi: Real-world health care data platform providing secure access to de-identified clinical data from UPMC's patient population to accelerate discoveries and improve patient care.
  • Center for Connected Medicine (CCM)
  • Pittsburgh Health Data Alliance (PHDA)

Products and services

  • Ahavi Real-World Data Platform Real-world healthcare data platform providing secure access to de-identified clinical data from UPMC's patient population (5M+ patients across 24 hospitals), enabling AI model validation, clinical trial design, and research acceleration by integrating structured and unstructured data from EHRs, radiology, and pathology reports.
  • UPMC Sponsored Clinical Trials and Partnerships Centralized clinical trial management program providing industry sponsors streamlined access to UPMC's clinical research infrastructure, featuring OnCore CTMS and Ahavi real-world data integration. Activates approximately 200-250 industry-sponsored trials annually across more than 25 departments.
  • Healthcare Investment Portfolio Evergreen investment platform deploying capital from early- to growth-stage in healthcare innovation companies, providing portfolio companies with capital, connections, and resources including access to UPMC's clinical infrastructure for validation and pilots.

Quantifiable outcome

  • Ahavi delivers normalized and de-identified datasets within 2-4 weeks, significantly faster than traditional methods
  • +2 more outcomes

Companies that use UPMC Enterprises

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

UPMC Enterprises technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability9 records

Feature4 records

UPMC Enterprises partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • Penguin AIcoreStrategic or Co-development Partner · 12 November 2025UPMC Enterprises entered a strategic partnership with Penguin AI to advance healthcare-specific AI models using UPMC's Ahavi secure data platform. Through the collaboration, Penguin AI leverages Ahavi to develop healthcare AI systems including Patient 360 and Enhanced Prior Authorization, designed to improve clinical decision-making and reduce administrative burdens.
  • Carnegie Mellon UniversitycoreStrategic or Co-development PartnerUPMC Enterprises participated as judges in the Forge to Field AI Pitch Competition hosted by Carnegie Mellon University's Swartz Center for Entrepreneurship and AI Strike Team, distributing over $1.75 million in potential investments during NFL Draft Week.
  • NokiacoreStrategic or Co-development PartnerNokia supports the Center for Connected Medicine at UPMC, collaborating with UPMC Enterprises to bring together leaders and innovators striving to advance healthcare through programming that informs, connects, and inspires.
  • KLAS ResearchcoreStrategic or Co-development PartnerUPMC Enterprises and KLAS Research collaborate on healthcare research including reports on precision medicine, clinical trials, AI in healthcare, and ambulatory care strategies at health systems.
  • Realyze Intelligence (Acquired by Carta Healthcare)minorStrategic or Co-development PartnerCarta Healthcare acquired Realyze Intelligence from UPMC Enterprises in November 2024 to expand into clinical trials. This built on prior collaboration in clinical data management.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

UPMC Enterprises competitors and assessment

Company assessment

Direct peers

  • OSF Ventures: The venture arm of OSF HealthCare, a large integrated Catholic health system. Direct peer because it invests in digital health and care delivery startups using OSF's clinical network, very similar in structure and scale to UPMC Enterprises.
  • Optum Ventures: The corporate venture arm of UnitedHealth Group's Optum, investing across healthcare AI, digital health, and care delivery. Direct peer because it operates the same model: a CVC funded by a major integrated payer-provider, leveraging clinical and data assets to back healthcare innovation companies.
  • Mayo Clinic Ventures: The technology transfer and venture arm of Mayo Clinic. Direct peer because it commercializes clinical innovations and invests in healthcare startups using Mayo's clinical research infrastructure—essentially the same role UPMC Enterprises plays within UPMC.
  • Kaiser Permanente Ventures: The strategic venture arm of Kaiser Permanente, one of the largest integrated US health systems. Direct peer because it invests across healthcare technology and services using Kaiser's clinical infrastructure and patient population, mirroring UPMC Enterprises' model.
  • Cleveland Clinic Innovations: The commercialization and venture arm of Cleveland Clinic. Direct peer because it spins out and invests in healthcare companies leveraging Cleveland Clinic's clinical expertise and IP, paralleling UPMC Enterprises' Translational Sciences function.
  • Memorial Hermann Innovation: The innovation and venture arm of Memorial Hermann Health System. Comparable to UPMC Enterprises as a regional health system-backed CVC deploying capital and clinical infrastructure into digital health and care delivery startups.
  • Geisinger Ventures: The investment and commercialization arm of Geisinger Health. Comparable to UPMC Enterprises as a Pennsylvania-based integrated health system CVC focused on healthcare technology innovation and translational research.

Broad incumbents

  • Andreessen Horowitz (Bio/Health): A major independent venture firm with dedicated bio/health funds. Comparable in that it invests across the same healthcare AI and biotech categories that UPMC Enterprises targets, but at much greater scale and from a pure-financial-return perspective.
  • General Catalyst (Health): A leading independent VC with a dedicated health system transformation practice partnering with major US health systems. Adjacent to UPMC Enterprises because it competes for healthcare AI and digital health deals, though it operates without corporate-parent backing.
  • Bessemer Venture Partners (Healthcare): Major independent venture firm with a substantial healthcare practice. Comparable to UPMC Enterprises in that it actively invests across healthcare AI, biotech, and digital health—but operates as an independent VC rather than a corporate subsidiary.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

UPMC Enterprises social profiles

Digital presence

UPMC Enterprises financial estimates

Financial estimate

Revenue estimate

Valuation estimate

UPMC Enterprises leadership team

Management profile

Number of profiles

Profiles20 records

UPMC Enterprises funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

UPMC Enterprises M&A and investment

M&A and investment

M&A

Investments55 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about UPMC Enterprises

What does UPMC Enterprises do?

UPMC Enterprises operates as the innovation, commercialization, and venture capital arm of UPMC, investing in early- to growth-stage healthcare companies across Therapeutics, Digital Health, and Translational Sciences. It also operates the Ahavi real-world healthcare data platform, which provides secure access to de-identified clinical data from UPMC's patient population, and manages the UPMC Sponsored Clinical Trials and Partnerships program for industry sponsors.

Is UPMC Enterprises a public or private company?

UPMC Enterprises is a private company. It is classified as corporate owned and is currently operating.

When was UPMC Enterprises founded?

UPMC Enterprises was founded in 2015. It employs 101 to 250 people.

Where is UPMC Enterprises based?

UPMC Enterprises is headquartered in Pittsburgh, United States, in the North America region.

How does UPMC Enterprises make money?

Two revenue lines are on record. Venture Capital Returns are the primary driver. The others are clinical Trials Services.

Who are UPMC Enterprises's main competitors?

Direct peers on record are OSF Ventures, Optum Ventures, Mayo Clinic Ventures, Kaiser Permanente Ventures, Cleveland Clinic Innovations, Memorial Hermann Innovation and Geisinger Ventures. Broad incumbents are Andreessen Horowitz (Bio/Health), General Catalyst (Health) and Bessemer Venture Partners (Healthcare).

Does UPMC Enterprises have an API?

No public API is recorded for UPMC Enterprises.

What industry is UPMC Enterprises in?

UPMC Enterprises's product category is Healthcare Venture Capital and Innovation Services. Its primary akta.pro industry code is FSANAHAF, Corporate Strategic Partnership & Ecosystem Investment Arms, with a secondary code of FSANAHAL, Corporate Deep Tech / R&D Commercialization CVC. Its NAICS code is 55111 and its SIC code is 6211.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
American City Business JournalsUPMC Enterprises invests in VeloSourceVeloSource will use the capital to develop a contingent staffing management program that can be replicated across health systems nationwide. The article is a paywall teaser, with the remainder reserved for subscribers.MedCity NewsUPMC Enterprises Invests in VeloSource to Expand AI-Enabled Clinician Staffing PlatformUPMC Enterprises invested in VeloSource to expand its AI-enabled clinician staffing platform Syncx. The investment aims to address physician shortages, with the federal HHS projecting a 141,160-physician shortfall by 2038. UPMC will use Syncx to manage its workforce and anticipate future staffing needs.EIN PresswireUPMC Enterprises Invests in VeloSource to Expand AI-Enabled Clinician Staffing Platform - MedCity NewsUPMC Enterprises invested in VeloSource to expand its AI-enabled clinician staffing platform, Syncx. The investment aims to address physician shortages, with the U.S. projected to face a 141,160-physician gap by 2038. UPMC will use Syncx to manage its workforce and anticipate future staffing needs.PrwebUPMC Enterprises Makes Strategic Investment in Contingent Staffing Technology to Address National Physician Workforce ChallengesUPMC Enterprises made a strategic investment in VeloSource, a locum tenens staffing firm powered by Syncx, to develop AI-enabled staffing technology. Dr. Richard Wadas will become VeloSource's Chief Medical Officer, and UPMC Enterprises will hold a board seat. The investment aims to address a projected national physician shortfall of 141,160 by 2038.Pulse 2.0ai3Bio Raises $48 Million Series A To Develop Autoimmune Disease Therapiesai3Bio raised $48 million in Series A funding led by UPMC Enterprises and Ziff Capital Partners to develop therapies targeting pathogenic Th17 cells in autoimmune diseases. The company will use the funds for IND-enabling studies and advancing its STARx and T Deplete platforms toward first-in-human trials.citybizAi3Bio Launches With $48M Series A to Reset Immune SystemAi3Bio closed a $49 million Series A led by UPMC Enterprises and Ziff Capital Partners to target autoimmune diseases like rheumatoid arthritis and diabetes. The company's antibody and lipid nanoparticle platforms aim to eliminate disease-causing Th17 cells in a single step, with safety data from non-human primate models.The Pharma Letterai3Bio launches with $48 million to eliminate disease-causing Th17 cellsai3Bio, a US biotech, launched with $48 million in Series A funding led by UPMC Enterprises and Ziff Capital Partners. The Watertown, Massachusetts-based company is advancing two platforms to directly target and eliminate disease-causing Th17 cells in vivo, rather than broadly suppressing inflammation.BioSpaceGenSight Biologics Reports Interim Financial Results for the First Half of 2026 and Provides Business UpdatesGenSight Biologics reported H1 2026 IFRS revenue of €(1.2) million, down from €(0.2) million, after collecting €6.5 million in early access payments. Operating cash burn fell 37% to €1.6 million, and manufacturing transfer to Catalent was completed. The company seeks structural financing for the RECOVER Phase III trial, expected to start in H2 2027.Business Wire Blogai3Bio Launches with $48 Million in Series A Funding to Reset the Immune System at Its Rootai3Bio announced its launch with $48 million in Series A funding led by UPMC Enterprises and Ziff Capital Partners. The company's platforms target and eliminate disease-causing Th17 cells in vivo, with IND-enabling studies underway. The capital will advance both platforms toward first-in-human trials.Venture Capital Access Onlineai3Bio Launches with $48 Million in Series A Funding to Reset the Immune System at Its Rootai3Bio launched with $48 million in Series A funding led by UPMC Enterprises and Ziff Capital Partners. The company's STARx and T Deplete platforms target disease-causing Th17 cells in vivo, with IND-enabling studies underway. The capital will advance first-in-human trials for autoimmune disease.